Insider Trading March 23, 2026

ReposiTrak CEO Randall Fields Sells $60K of Stock as Company Announces Operational Moves

Fields executed an automated sale of 7,500 shares; ReposiTrak reports a new loan facility, dividend and board appointment amid product and partnership updates

By Priya Menon TRAK
ReposiTrak CEO Randall Fields Sells $60K of Stock as Company Announces Operational Moves
TRAK

Summary - ReposiTrak (NASDAQ:TRAK) Chief Executive Officer Randall K. Fields sold 7,500 shares of common stock on March 23, 2026, generating about $60,447 in proceeds. The disposal was completed under a pre-established Rule 10b5-1 plan at prices between $8.00 and $8.17. The company announced several corporate developments, including a loan agreement between subsidiary PC Group, Inc. and SPAR Marketing Force, Inc.; a quarterly dividend; a board reappointment; a patent-pending traceability technology; and an expanded partnership with the National Grocers Association.

Key Points

  • CEO Randall K. Fields sold 7,500 shares on March 23, 2026 under a Rule 10b5-1 plan for about $60,447 at prices between $8.00 and $8.17.
  • Post-transaction holdings include Fields' direct ownership of 3,483,955 shares, and notable affiliate holdings by RK Fields Charitable 2022, LLC; Riverview Financial Corp.; Fields Management, Inc.; and Fields' spouse.
  • Corporate developments: a $4 million loan facility via subsidiary PC Group, Inc. with SPAR Marketing Force (initial $3M advance and $1M available July 17, 2026); a $0.02 quarterly dividend with record date March 31, 2026 and payment May 15, 2026; board reappointment of James R. Gillis; a patent-pending food traceability error-detection and correction technology; and expanded partnership with the National Grocers Association.

Transaction details

On March 23, 2026, ReposiTrak Chief Executive Officer Randall K. Fields sold 7,500 shares of the company's common stock for roughly $60,447. Reported sale prices ranged from $8.00 to $8.17 per share. The sale was carried out automatically under a pre-arranged Rule 10b5-1 trading plan.

The company's share price is trading at $8.07, which is close to its 52-week low of $7.76 and represents a 60% decline over the past year. Despite the recent price weakness, InvestingPro analysis referenced by the company indicates the stock appears undervalued on Fair Value metrics and notes ReposiTrak's gross profit margins of 85%.

Insider and affiliated holdings after the sale

Following the sale, Fields directly holds 3,483,955 shares of ReposiTrak common stock. Associated entities and family holdings disclosed in filings include:

  • RK Fields Charitable 2022, LLC - 70,000 shares of common stock
  • Riverview Financial Corp. - 615,260 shares of common stock and 169,797 shares of Series B Preferred Stock
  • Fields Management, Inc. - 333,643 shares of common stock
  • Fields' spouse - 30,667 shares of common stock and 3,704 shares of Series B Preferred Stock

Corporate and operational updates

Separately, ReposiTrak disclosed several company developments intended to support its operations and market positioning. Its subsidiary, PC Group, Inc., entered a loan agreement with SPAR Marketing Force, Inc., providing a credit facility of up to $4 million. The facility is structured in two tranches: an initial advance of $3 million and an additional $1 million that becomes available beginning July 17, 2026.

The company also declared a quarterly dividend of $0.02 per share, with a record date set for March 31, 2026, and a payment scheduled for May 15, 2026.

On the corporate governance front, ReposiTrak said James R. Gillis has returned to the company's board of directors. Management highlighted the introduction of a patent-pending technology designed to automatically detect and correct errors in food traceability data. The company further announced an expansion of its strategic partnership with the National Grocers Association to bolster regulatory compliance and financial performance for independent grocers.

Context and closing

These announcements accompany the disclosed insider sale and the firm’s current market valuation debate noted by InvestingPro. The filings provide a detailed breakdown of insider and affiliate holdings following the sale and outline financing and operational initiatives intended to support ReposiTrak's business activities.

Risks

  • Market risk: The stock is trading near its 52-week low ($7.76) and is down 60% over the past year, which may reflect investor concerns about valuation or performance.
  • Financing risk: The company’s subsidiary entered a $4 million loan arrangement in two tranches, which creates reliance on external financing availability, including the $1 million tranche that becomes available on July 17, 2026.
  • Execution risk: The company plans to roll out a patent-pending traceability technology and expand partnerships; successful commercial adoption and regulatory compliance outcomes are not guaranteed by the disclosures.

More from Insider Trading

Adaptive Biotechnologies President Rubinstein Disposes $769K in Shares, Exercises Options Mar 23, 2026 Director Ault Adds 24,000 Shares to Universal Safety Products Stake in Three Trades Mar 23, 2026 Sprouts VP Sells Shares to Cover Taxes as Analysts Trim Targets Mar 23, 2026 Sprouts CTO Sells 208 Shares to Cover RSU Taxes as Analysts Trim Targets After Q4 Beat Mar 23, 2026 Sprouts CFO Disposes $21,244 in Shares as Analysts Adjust Targets Mar 23, 2026